Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Follow-Up of Subjects Treated With NTLA-2001

NCT05697861 is registered in ClinicalTrials.gov with Intellia Therapeutics as lead sponsor.

NCT NCT05697861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05697861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Follow-Up of Subjects Treated With NTLA-2001
Lead sponsor
Intellia Therapeutics
Phase
Observational
Overall status
Enrolling by invitation
Start date
July 10, 2023
Completion date
March 31, 2038
Enrollment
72 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin-related (attr) familial amyloid cardiomyopathy, transthyretin-related (attr) familial amyloid polyneuropathy, wild-type transthyretin cardiac amyloidosis